These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

852 related items for PubMed ID: 25424958

  • 1. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.
    Ilyina N, Kharit S, Namazova-Baranova L, Asatryan A, Benashvili M, Tkhostova E, Bhusal C, Arora AK.
    Hum Vaccin Immunother; 2014; 10(8):2471-81. PubMed ID: 25424958
    [Abstract] [Full Text] [Related]

  • 2. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J, Nolan T, Richmond P, Reynolds G, Nissen M, Lambert SB, Marshall H, Papa T, Rehm C.
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA, Greenberg DP, Hedrick J, Pichichero M, Decker MD, Saunders M.
    Vaccine; 2016 Oct 17; 34(44):5273-5278. PubMed ID: 27642132
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
    Klein NP, Habanec T, Kosina P, Shah NR, Kolhe D, Miller JM, Hezareh M, Van der Wielen M.
    Vaccine; 2018 Apr 19; 36(17):2356-2363. PubMed ID: 29576307
    [Abstract] [Full Text] [Related]

  • 5. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
    Block SL, Szenborn L, Daly W, Jackowska T, D'Agostino D, Han L, Dull PM, Smolenov I.
    Vaccine; 2015 May 15; 33(21):2500-10. PubMed ID: 25795256
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
    Peterson J, Drazan D, Czajka H, Maguire J, Pregaldien JL, Seppa I, Maansson R, O'Neill R, Balmer P, Jodar L, Jansen KU, Anderson AS, Perez JL, Beeslaar J.
    Lancet Infect Dis; 2023 Dec 15; 23(12):1370-1382. PubMed ID: 37579773
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults.
    Beran J, Dražan D, Enweonye I, Bhusal C, Toneatto D.
    mSphere; 2021 Dec 22; 6(6):e0055321. PubMed ID: 34787449
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
    Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM.
    Pediatr Infect Dis J; 2015 Dec 22; 34(12):e298-307. PubMed ID: 26780033
    [Abstract] [Full Text] [Related]

  • 9. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
    Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM, V59P13 Study Group.
    Clin Infect Dis; 2009 Jul 01; 49(1):e1-10. PubMed ID: 19476428
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth.
    Warshaw MG, Siberry GK, Williams P, Decker MD, Jean-Philippe P, Lujan-Zilbermann J.
    J Pediatric Infect Dis Soc; 2017 Sep 01; 6(3):e69-e74. PubMed ID: 28339668
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
    Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ.
    JAMA; 2008 Jan 09; 299(2):173-84. PubMed ID: 18182599
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.
    Saez-Llorens X, Aguilera Vaca DC, Abarca K, Maho E, Graña MG, Heijnen E, Smolenov I, Dull PM.
    Hum Vaccin Immunother; 2015 Jan 09; 11(6):1507-17. PubMed ID: 25969894
    [Abstract] [Full Text] [Related]

  • 13. Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.
    Siberry GK, Warshaw MG, Williams PL, Spector SA, Decker MD, Jean-Philippe P, Yogev R, Heckman BE, Manzella A, Roa J, Nachman S, Lujan-Zilbermann J, IMPAACT P1065 Protocol Team.
    Pediatr Infect Dis J; 2012 Jan 09; 31(1):47-52. PubMed ID: 21987006
    [Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years.
    Lalwani S, Agarkhedkar S, Gogtay N, Palkar S, Agarkhedkar S, Thatte U, Vakil H, Jonnalagedda R, Pedotti P, Hoyle M, Bhusal C, Arora A.
    Int J Infect Dis; 2015 Sep 09; 38():36-42. PubMed ID: 26166699
    [Abstract] [Full Text] [Related]

  • 15. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.
    Siberry GK, Williams PL, Lujan-Zilbermann J, Warshaw MG, Spector SA, Decker MD, Heckman BE, Demske EF, Read JS, Jean-Philippe P, Kabat W, Nachman S, IMPAACT P1065 Protocol Team.
    Pediatr Infect Dis J; 2010 May 09; 29(5):391-6. PubMed ID: 20431379
    [Abstract] [Full Text] [Related]

  • 16. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
    Hu JL, Tao H, Li JX, Dai WM, Song B, Sun JF, Liu P, Tang J, Liu WY, Wang SY, Zhu FC.
    Hum Vaccin Immunother; 2015 May 09; 11(5):1120-8. PubMed ID: 25833163
    [Abstract] [Full Text] [Related]

  • 17. Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source.
    Gill CJ, Ram S, Welsch JA, Detora L, Anemona A.
    Vaccine; 2011 Dec 09; 30(1):29-34. PubMed ID: 22075087
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates.
    Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P.
    Clin Vaccine Immunol; 2011 Mar 09; 18(3):483-6. PubMed ID: 21177912
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT.
    Findlow H, Borrow R.
    Adv Ther; 2013 May 09; 30(5):431-58. PubMed ID: 23712402
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults.
    Lee HJ, Chung MH, Kim WJ, Hong YJ, Choi KM, Lee J, Oh CE, Welsch JA, Kim KH, Hong KB, Dagnew AF, Bock H, Dull PM, Odrljin T.
    Int J Infect Dis; 2014 Nov 09; 28():204-10. PubMed ID: 25316331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.